An interventional study of AGN1 LOEP in Osteoporosis, sponsored by AgNovos Healthcare, LLC. Recruiting at 1 site in Belgium. Open to female participants. Per ClinicalTrials.gov, last updated 2025-01-31.
Sponsored by AgNovos Healthcare, LLC · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Osteoporosis with a site in Belgium — 4 open to participants now, 5 under way, none of them phase 3. Osteoporosis · Belgium.
Among the 32 studies in Osteoporosis with a site in Belgium, this one is the 17th largest by planned enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2021, is one of 9 with no phase, and was the 29th registered.
1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.
Browse Osteoporosis studies →4 of the 32 studies in Osteoporosis with a site in Belgium are open now. Recruiting first, the newest first:
Imelda Hospital, Bonheiden · Sites in Belgium
Ages 55+
AgNovos Healthcare, LLC · Sites in Belgium, Austria, Canada and 8 more countries
Ages 65–91 · Women only
AgNovos Healthcare, LLC · Sites in Belgium
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 218 across the 27 interventional studies, 54 across the 5 observational. Of the 26 that completed or were terminated, 14 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
24 of 32 have an industry lead sponsor. The 10 most frequent:
AgNovos Healthcare, LLC is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
AgNovos Healthcare, LLC has 7 studies filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
2 of the studies in Osteoporosis with a site in Belgium that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07594639AgNovos Healthcare, LLCGRACE II (General Retrospective Analysis of Commercial Experience With AGN1 LOEP) | 2027-04-01 |
| NCT04796350AgNovos Healthcare, LLCRESTORE - Study of AGN1 LOEP to Prevent Secondary Hip Fractures | 2027-04-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Osteoporosis with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The research will be conducted as a prospective, post-market, multi-center study within Europe. The maximum number of subjects to be treated is 150 across up to 20 sites. This will be a non-randomized and open-label study. The study will collect procedural, short- and long-term data on the safety and clinical performance of AGN1 LOEP in the post-market setting in European countries where AGN1 LOEP is commercially available. AGN1 is intended to form new bone in voids in the proximal femur of women with osteoporosis.
To qualify for this study, a subject must have at least one intact hip with bone loss attributable to osteoporosis as indicated by a femoral neck DXA T-score of -2.5 or less.
Follow-up visits will be conducted at 10 days, 42 days, 12 months, and 24 months after the procedure. Study evaluations at each follow-up visit include general health (physical exam and medical history update), VAS pain (not at 10 days), FES-I (not at 10 days), EQ5D-5L and Parker Mobility. A Timed Up and Go Test is performed at the 10-day, 42-day and 12-month follow-up. Patient satisfaction with outcome of surgery will be asked at the 42-day and the 12-month follow-up. DXA scans and X-rays will be performed at 12 and 24 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects treated with AGN1 LOEP in proximal femur
Device: AGN1 LOEP
Subjects with osteoporosis are treated with AGN1 local osteo-enhancement procedure in the proximal femur
Femoral Neck Bone Mineral Density
6% increase in mean femoral neck BMD from preprocedure baseline to 12 months post-procedure of treated hips
Time frame: 12 months
Primary Safety Evaluation
The incidence of all adverse events and serious adverse events occurring post-AGN1 LOEP through the 12 months follow-up period determined to be at least possibly related to the procedure and/or device.
Time frame: 12 months
Total Hip Bone Mineral Density
6% increase in mean total hip BMD from preprocedure baseline to 12 months post-procedure of treated hips.
Time frame: 12 months
Femoral Neck Bone Mineral Density
6% increase in mean femoral neck BMD from preprocedure baseline to 24 months post-procedure of treated hips.
Time frame: 24 months
Total Hip Bone Mineral Density
6% increase in mean total hip BMD from preprocedure baseline to 24 months post-procedure of treated hips.
Time frame: 24 months
Bone Formation
Radiologic appearance of bone formation as assessed by X-ray at 12 and 24 months post-procedure of treated hips.
Time frame: 12 and 24 months
Patient Satisfaction
Patient satisfaction with outcome of surgery in the treated hip(s) and overall at 42 days and 12 months assessed with Visual Analogue Scale.
Time frame: 42 days and 12 months
Pain hip
Pain (left hip, right hip) at baseline, 42 days, 12 months, and 24 months assessed with Visual Analogue Scale.
Time frame: baseline, 42 days, 12 months, and 24 months.
Pain body overall
Pain body overall at baseline, 42 days, 12 months, and 24 months assessed with Visual Analogue Scale.
Time frame: baseline, 42 days, 12 months, and 24 months.
FES-I
FES-I at baseline, 42 days, 12 months, and 24 months
Time frame: baseline, 42 days, 12 months, and 24 months
Quality of Life with EQ5D-5L
EQ5D-5L at baseline, 10 days, 42 days, 12 months, and 24 months
Time frame: baseline, 10 days, 42 days, 12 months, and 24 months
Parker Mobility Score
Parker Mobility Score at baseline, 10 days, 42 days, 12 months, and 24 months.
Time frame: baseline, 10 days, 42 days, 12 months, and 24 months.
Verifying the enhancement site
The ability to access the enhancement site by drilling through the lateral femoral cortex of the proximal femur and to determine the boundaries of the enhancement site using the probe debrider.
Time frame: Procedure (day 0)
Technical Success
The ability to deliver the necessary amount of AGN1 material to adequately fill the osseous defect as assessed by the treating surgeon.
Time frame: Procedure (day 0)
SAE
Incidence of all serious adverse events post-AGN1 LOEP through the 24 months follow-up period.
Time frame: 24 months
Hip Fracture
Incidence of new hip fractures on the treated side.
Time frame: 24 months
Timed up and go test
Timed up and go test at baseline, 10 days, 42 days and 12 months.
Time frame: baseline, 10 days, 42 days and 12 months.
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2021 (actual). Primary completion is estimated for Dec 2025, 53 months after the start.
Of 239 interventional studies with no phase under Osteoporosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 50. This study's planned 53 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AgNovos Healthcare, LLC